<SEC-DOCUMENT>0001104659-21-045257.txt : 20210401
<SEC-HEADER>0001104659-21-045257.hdr.sgml : 20210401
<ACCEPTANCE-DATETIME>20210401085809
ACCESSION NUMBER:		0001104659-21-045257
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210331
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210401
DATE AS OF CHANGE:		20210401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		21796182

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2111564d1_8k.htm
<DESCRIPTION>FORM-8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
<U>March&nbsp;31, 2021</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>EYENOVIA,&nbsp;INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Delaware</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">001-38365</TD>
    <TD STYLE="padding-bottom: 1pt; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U></U></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">47-1178401</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">295 Madison Avenue, Suite&nbsp;2400, New York, New York 10017</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Zip Code)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area code
<U>(917) 289-1117</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Title of each class</TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Trading Symbol(s)</TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Name of each exchange on which registered</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Common Stock, $0.0001 Par Value</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EYEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Nasdaq Capital Market</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this Chapter) or Rule&nbsp;12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this Chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;31, 2021, the Board of Directors (the &ldquo;Board&rdquo;) of Eyenovia,&nbsp;Inc. (the &ldquo;Company&rdquo;) appointed
Julia A. Haller, M.D. as a member of the Board, effective immediately, to serve until the Company&rsquo;s 2021 annual meeting of
stockholders or until her successor is duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr.&nbsp;Haller, age 66, has served since 2007
as Ophthalmologist-in-Chief at Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, M.D. Endowed Chair. She also
is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson
University Hospitals. Prior to her current positions, Dr.&nbsp;Haller trained at the Wilmer Eye Institute at Johns Hopkins where she served
as the first female Chief Resident.&nbsp; She then joined the Johns Hopkins faculty, where she directed the retina fellowship program
and held the Katharine Graham Chair in Ophthalmology.&nbsp;&nbsp;One of the world's most renowned retinal surgeons, Dr.&nbsp;Haller has
published over 400 scientific articles and book chapters and innovated translational advances against blindness in many areas. Elected
to the National Academy of Medicine, Dr.&nbsp;Haller is recognized globally for her multiple accomplishments in ophthalmology. Dr.&nbsp;Haller
currently serves on the board of directors of Bristol-Myers Squibb Company&nbsp;(NYSE: BMY) and served on the board of directors of Celgene
Corporation, prior to its acquisition by Bristol-Myers Squibb in 2019. She also is president and serves on the board of directors of the
Women in Medicine Legacy Foundation, chairs the Heed Foundation and Society of Heed Fellows, is a member of the board of directors of
the College of Physicians of Philadelphia, Johns Hopkins Medical and Surgical Association, and the Philadelphia Orchestra Association,
and is a member of the American Ophthalmological Society Council, and the American Academy of Ophthalmology Foundation board of advisors.
Dr.&nbsp;Haller&rsquo;s editorial board service includes RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, and
Ophthalmology Times. Dr.&nbsp;Haller holds an A.B. in philosophy from Princeton University, where she graduated magna cum laude, and an
M.D. from Harvard University Medical School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board has determined that Dr.&nbsp;Haller is
an independent director under relevant SEC and Nasdaq rules. There are no arrangements or understandings between Dr.&nbsp;Haller and any
other person pursuant to which she was appointed as a director of the Board. T<FONT STYLE="color: #212529">here have been no transactions
in which the Company has participated and in which Dr.&nbsp;Haller has had a direct or indirect material interest that would be required
to be disclosed under Item 404(a)&nbsp;of Regulation S-K. </FONT>Dr.&nbsp;Haller has not been appointed to any Board committee at this
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><B>Item&nbsp;9.01.</B></TD>
    <TD STYLE="text-align: left; font-size: 10pt; width: 90%"><B>Financial Statements and Exhibits.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(d)</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">Exhibits</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; width: 7%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; width: 9%"><B>Exhibit&nbsp;No.</b></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 80%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2111564d1_ex99-1.htm">99.1</A></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2111564d1_ex99-1.htm">Press release dated April&nbsp;1, 2021. </A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>EYENOVIA,&nbsp;INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;April&nbsp;1, 2021</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ John Gandolfo</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: John Gandolfo</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2111564d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2111564d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eyenovia Announces Appointment of Renowned Ophthalmologist
and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Scientific Leader Dr.&nbsp;Julia Haller to its
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK &ndash; April&nbsp;1, 2021&mdash;<U>Eyenovia,&nbsp;Inc.
</U>(NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose
array print (MAP&trade;) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia
Haller, M.D., to its Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are delighted to welcome Dr.&nbsp;Haller
to our Board of Directors at such an exciting time for Eyenovia,&rdquo; commented Dr.&nbsp;Sean Ianchulev, Chief Executive Officer and
Chief Medical Officer of&nbsp;Eyenovia. &ldquo;We believe that Dr.&nbsp;Haller&rsquo;s decades of experience as an esteemed ophthalmic
surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic
pipeline and work towards our near-term clinical and regulatory milestones.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I have been familiar with Eyenovia and
its MAP technology for some time now and believe the Company&rsquo;s proprietary programs have the potential to become new standards of
care in ophthalmic indications with significant unmet needs,&rdquo; stated Dr.&nbsp;Haller. &ldquo;I look forward to working with my fellow
Eyenovia Board members and the leadership team to help create advances in the field.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Since 2007, Dr.&nbsp;Haller
has served as Ophthalmologist-in-Chief at Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair.
She also is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and
Thomas Jefferson University Hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">One of the world's most
renowned retinal surgeons, Dr.&nbsp;Haller has published over 400 scientific articles and book chapters and innovated translational advances
against blindness in many areas. Elected to the National Academy of Medicine, Dr.&nbsp;Haller, has been awarded the Rolex Achievement
Award, the American Academy of Ophthalmology (AAO) Honor Award, the AAO Senior Achievement Award, the Vitreous Society Senior Honor Award,
the Crystal Apple Award (for mentorship) of the American Society of Retina Specialists (ASRS), the Kreissig Award from EURETINA, the President&rsquo;s
Award from Women in Ophthalmology (WIO), a Secretariat Award from the AAO, the Gertrude Pyron Award from the Retina Research Foundation/ASRS,
a Lifetime Achievement Award from the AAO, the Louis Braille Award from Associated Services for the Blind, the Heed Award from the Society
of Heed Fellows, the Gass Medal from the Macula Society, the Strittmatter Award from the Philadelphia Medical Society (their highest honor),
the AAO EnergEYES Award, the WIO Suzanne V&eacute;ronneau-Troutman Award, the Charles L. Schepens, MD, Award from the Retina Research
Foundation/AAO and election to the Johns Hopkins Society of Scholars. She holds Chair XVI of the Academia Ophthalmologica Internationalis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dr.&nbsp;Haller serves
on the board of directors of Bristol-Myers Squibb Company. She also serves as president and board member for the Women in Medicine Legacy
Foundation. Dr.&nbsp;Haller chairs the Heed Foundation and Society of Heed Fellows, is a member of the board of directors of the College
of Physicians of Philadelphia, Johns Hopkins Medical and Surgical Association, and the Philadelphia Orchestra Association, and is a member
of the American Ophthalmological Society Council and the American Academy of Ophthalmology Foundation board of advisors. She is past president
of the Retina Society and the American Society of Retina Specialists and was previously a member of the Board of Trustees of the Association
of University Professors of Ophthalmology, as well as a founding member of Women in Retina.&nbsp;Her editorial board service includes
RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, and Ophthalmology Times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2111564d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dr.&nbsp;Haller was educated
at Princeton University, where she graduated magna cum laude, and at Harvard Medical School, where she earned her M.D. She trained at
the Wilmer Eye Institute at Johns Hopkins, where she served as the first female Chief Resident.&nbsp; She then joined the Johns Hopkins
faculty, where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology before her current position
leading Wills Eye Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About&nbsp;Eyenovia,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia,&nbsp;Inc.&nbsp;(NASDAQ: EYEN) is a
clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP&trade;)
platform technology. &nbsp;Eyenovia&nbsp;is currently focused on the late-stage development of medications for presbyopia, myopia progression
and mydriasis. For more Information, visit&nbsp;<U>www.eyenovia.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for historical information, all of the
statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include,
but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements
relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates
and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part,
on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions
that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed
or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the&nbsp;U.S.
Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other
things: our ability to attract and retain key personnel; risks of our and our licensees&rsquo; clinical trials, including, but not limited
to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing),
timing, progress and results of such trials; the timing and our and our licensees&rsquo; ability to submit applications for, obtain and
maintain regulatory approvals for our product candidates; the potential advantages of our product candidates and platform technology;
the rate and degree of market acceptance and clinical utility of our product candidates; intellectual property risks; changes in legal,
regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory
approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made,
and except as may be required under applicable securities laws,&nbsp;Eyenovia&nbsp;does not undertake any obligation to update any forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eyenovia Contact:</B><BR>
Eyenovia,&nbsp;Inc.<BR>
John Gandolfo<BR>
Chief Financial Officer<BR>
<U>jgandolfo@eyenovia.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eyenovia Investor Contact:</B><BR>
Eric Ribner<BR>
LifeSci Advisors, LLC<BR>
<U>eric@lifesciadvisors.com</U><BR>
(646) 751-4363</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eyenovia Media Contact:</B><BR>
Sam Choinski<BR>
Pazanga Health Communications<BR>
schoinski@pazangahealth.com<BR>
(603) 489-5964</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2111564d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2111564d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) +P# 2(  A$! Q$!_\0
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M+CNAQJ1E\+N/HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
